Skip to main content

Advertisement

Log in

Tic disorders: from pathophysiology to treatment

  • REVIEW
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Tic disorders are stereotypic behaviours,more frequent than once believed, and therefore likely to be encountered by primary care physicians. Tics usually begin in childhood and are the clinical hallmark of Tourette Syndrome (TS), the most common cause of tics. TS is a relatively common neurobehavioural disorder with a spectrum of manifestations that wax and wane during its natural course. The pathophysiology of tics, at molecular and cellular level, is still unknown,whereas structural and functional neuroimaging studies have shown the involvement of the basal ganglia and related cortico–striato–thalamo–cortical circuits, and the dopaminergic neuronal system. Moreover, TS has a strong genetic background. The management of TS is often complicated by the presence of attention–deficit/hyperactivity disorder, obsessivecompulsive disorder, and other behaviour disorders. The correct diagnosis is a fundamental step for a proper management of these disorders, and a multimodal treatment is usually indicated. This approach includes educational and supportive interventions, as well as pharmacological treatments when tics are at their worst.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adams JR, Troiano AR, Calne DB (2004) Functional imaging in Tourette’s syndrome. J Neural Transm 111:1495–1506

    Article  CAS  PubMed  Google Scholar 

  2. Albin RL, Koeppe RA, Bohnen NI, Nichols TE, Meyer P, Wernette K, Minoshima S, Kilbourn MR, Frey KA (2003) Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology 61:310–315

    CAS  PubMed  Google Scholar 

  3. Allen AJ (1997) Group streptococcal infections and childhood neuropsychiatric disorder. Curr Opin 267:75

    Google Scholar 

  4. Almeras N, Despres JP, Villeneuve J, Demers MF, Roy MA, Cadrin C, Mottard JP, Bouchard RH (2004) Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry 65:557–564

    Article  CAS  PubMed  Google Scholar 

  5. Alsobrook JP, Pauls DL (1997) The genetics of Tourette syndrome. Neurol Clin 15:381–893

    PubMed  Google Scholar 

  6. Amann BL, Pogarell O, Mergl R, Juckel G, Grunze H, Mulert C, Hegerl U (2003) EEG abnormalities associated with antipsychotics: a comparison of quetiapine, olanzapine, haloperidol and healthy subjects. Hum Psychopharmacol 18:641–646

    CAS  PubMed  Google Scholar 

  7. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Assn 103

  8. Anca MH, Giladi N, Korczyn AD (2004) Ropinirole in Gilles de la Tourette syndrome. Neurology 62:1626–1627

    PubMed  Google Scholar 

  9. Awaad Y, Michon AM, Minarik S (2005) Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome. Mov Disord 20:714–718

    Article  PubMed  Google Scholar 

  10. Bagheri MM, Kerbeshian J, Burd L (1999) Recognition and management of Tourette’s syndrome and tic disorders. Am Fam Physician 59:2263–2272

    CAS  PubMed  Google Scholar 

  11. Begum M (2005) Clozapine–induced stuttering, facial tics and myoclonic seizures: a case report. Aust N Z J Psychiatry 39:202

    Article  CAS  PubMed  Google Scholar 

  12. Black KJ (2002) Tourette Syndrome and Other Tic Disorders Available from: http://www. eMedicine. com

  13. Black KJ, Mink JW (2000) Response to levodopa challenge in Tourette syndrome. Mov Disord 15:1194–1198

    Article  CAS  PubMed  Google Scholar 

  14. Bonnier C, Nassogne M, Evrard P (1999) Ketanserin Treatment of Tourette’s Syndrome in Children. Am J Psychiatry 156:1122–1123

    CAS  PubMed  Google Scholar 

  15. Bruggeman R, van der Linden C, Buitelaar JK (2001) Risperidone versus pimozide in Tourette’s disorder: a comparative double–blind parallelgroup study. J Clin Psychiatry 62:50–56

    Article  CAS  PubMed  Google Scholar 

  16. Carr JE, Bailey JS (1996) A brief behavior therapy protocol for Tourette syndrome. J Behav Ther Exp Psychiatry 27:33–40

    CAS  PubMed  Google Scholar 

  17. Chang HL, Tu MJ, Wang HS (2004) Tourette’s syndrome: psychopathology in adolescents. Psychiatry Clin Neurosci 58:353–358

    Article  PubMed  Google Scholar 

  18. Chappell PB, Riddle MA, Scahill L, Lynch KA, Schultz R, Arnsten A, Leckman JF, Cohen DJ (1995) Guanfacine treatment of comorbid attentiondeficit hyperactivity disorder and Tourette’s syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 34:1140–1146

    CAS  PubMed  Google Scholar 

  19. Cohen DJ, Jankovic J, Goetz CG (2001) Tourette syndrome. In: Advances in Neurology. Philadelphia, Pa: Lippincott Williams and Wilkins

  20. Crawford FC, Ait–Ghezala G, Morris M, Sutcliffe MJ, Hauser RA, Silver AA, Mullan MJ (2003) Translocation breakpoint in two unrelated Tourette syndrome cases, within a region previously linked to the disorder. Hum Genet 113:154–161

    CAS  PubMed  Google Scholar 

  21. Cuker A, State MW, King RA, Davis N, Ward DC (2004) Candidate locus for Gilles de la Tourette syndrome/obsessive compulsive disorder/chronic tic disorder at 18q 22.Am J Med Genet 130:37–39

    Google Scholar 

  22. Demirkiran M, Jankovic J (1995) Paroxysmal dyskinesias: clinical features and classification. Ann Neurol 38:571–579

    Article  CAS  PubMed  Google Scholar 

  23. Devor EJ, Magee HJ (1999) Multiple childhood behavioral disorders (Tourette syndrome, multiple tics, ADD, and OCD) presenting in a family with a balanced chromosome translocation (t1; 8)(q21. 1;q22. 1). Psychiatr Genet 9:149–151

    CAS  PubMed  Google Scholar 

  24. Dion Y, Annable L, Sandor P, Chouinard G (2002) Risperidone in the treatment of tourette syndrome: a double–blind, placebo–controlled trial. J Clin Psychopharmacol 22:31–39

    Article  CAS  PubMed  Google Scholar 

  25. Eapen V, Pauls DL, Robertson MM (1993) Evidence for autosomal dominant transmission in Tourette syndrome. Br J Psychiatry 162:593–596

    Article  CAS  PubMed  Google Scholar 

  26. Eichstedt JA, Arnold SL (2001) Childhood– onset obsessive–compulsive disorder: a tic–related subtype of OCD? Clin Psychol Rev 21:137–157

    CAS  PubMed  Google Scholar 

  27. Evidente VG (2000) Is it a tic or Tourette’s? Clues for differentiating simple from more complex tic disorders. Postgraduate Medicine 108:5

    Google Scholar 

  28. Fahn S (1988) Blepharospasm: a form of focal dystonia. Adv Neurol 49:125–133

    CAS  PubMed  Google Scholar 

  29. Fattapposta F, Restuccia R, Colonnese C, Labruna L, Garreffa G, Bianco F (2005) Gilles de la Tourette syndrome and voluntary movement: a functional MRI study. Psychiatry Res 138:269–272

    PubMed  Google Scholar 

  30. Fountoulakis KN, Iacovides A, St Kaprinis G (2004) Successful treatment of Tourette’s disorder with amisulpride. Ann Pharmacother 38:90

    Google Scholar 

  31. Fredericksen KA, Cutting LE, Kates WR, Mostofsky SH, Singer HS, Cooper KL, et al. (2002) Disproportionate increases of white matter in right frontal lobe in Tourette syndrome. Neurology 58:85–89

    CAS  PubMed  Google Scholar 

  32. Gaffney Gr, Perry PJ, Lund BC, Bever– Stille KA, Arndt S, Kuperman S (2002) Risperidone versus clonidine in the treatment of children and adolescents with Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 41:330–336

    PubMed  Google Scholar 

  33. Gaulin BD, Markowitz JS, Caley CF, Nesbitt LA, Dufresne RL (1999) Clozapine– Associated Elevation in Serum Triglycerides. Am J Psychiatry 156:1270–1272

    CAS  PubMed  Google Scholar 

  34. Gazdag G, Barna I, Ivanyi Z, Tolna J (2004) The impact of neuroleptic medication on seizure threshold and duration in electroconvulsive therapy. Ideggyogy Sz 57:385–390

    PubMed  Google Scholar 

  35. Gerber PE, Lynd LD (1998) Selective serotonin–reuptake inhibitor–induced movement disorders. Ann Pharmacother 32:692–698

    CAS  PubMed  Google Scholar 

  36. Gilbert DL, Batterson JR, Sethuraman G, Sallee FR (2004) Tic reduction with risperidone versus pimozide in a randomized, double–blind, crossover trial. J Am Acad Child Adolesc Psychiatry 43:206–214

    PubMed  Google Scholar 

  37. Gilbert DL, Dure L, Sethuraman G, Raab D, Lane J, Sallee FR (2003) Tic reduction with pergolide in a randomized controlled trial in children. Neurology 60:606–611

    CAS  PubMed  Google Scholar 

  38. Gilbert DL, Sallee FR, Zhang J, Lipps TD, Wassermann EM (2005) Transcranial Magnetic Stimulation–Evoked Cortical Inhibition: A Consistent Marker of Attention–Deficit/Hyperactivity Disorder Scores in Tourette Syndrome. Biol Psychiatry 57:1597–1600

    Article  PubMed  Google Scholar 

  39. Gilbert DL, Sethuraman G, Sine L, Peters S, Sallee FR (2000) Tourette’s syndrome improvement with pergolide in a randomized, double–blind, crossover trial. Neurology 54:1310–1315

    CAS  PubMed  Google Scholar 

  40. Goetz CG, Chmura TA, Lanska DJ (2001) History of tic disorders and Gilles de La Tourette syndrome: Part 5 of the MDS–sponsored history of movement disorders exhibit, Barcelona. Mov Disord 16:346–349

    CAS  PubMed  Google Scholar 

  41. Graybiel AM, Rauch SL (2000) Toward a neurobiology of obsessivecompulsive disorder. Neuron 28:343–347

    Article  CAS  PubMed  Google Scholar 

  42. Hallett JJ, Harling–Berg CJ, Knopf PM, Stopa EG, Kiessling LS (2000) Antistriatal antibodies in Tourette syndrome cause neuronal dysfunction. J Neuroimmunol 111:195–202

    Article  CAS  PubMed  Google Scholar 

  43. Hallett M (2001) Neurophysiology of tics. Adv Neurol 85:237–244

    CAS  PubMed  Google Scholar 

  44. Hamilton CS, Garvey MA, Swedo SE (2001) Therapeutic implications of immunology for tics and obsessivecompulsive disorder. Adv Neurol 85:311–318

    CAS  PubMed  Google Scholar 

  45. Hanna PA, Janjua FN, Contant CF (1999) Bilineal transmission in Tourette syndrome. Neurology 53:813–818

    CAS  PubMed  Google Scholar 

  46. Hanna PA, Jankovic J (2002) Sleep and tic disorders. In: Chokroverty S, Hening Walters A (eds) Sleep and movement disorders. Woburn, Mass Butterworth–Heinemann, pp 181–189

  47. Hoekstra PJ, Anderson GM, Limburgc PC, Korfd J, Kallenbergc CGM, Minderaa RB (2004) Neurobiology and neuroimmunology of Tourette’s syndrome: an update

  48. Hornsey H, Banerjee S, Zeitlin H, Robertson M (2001) The prevalence of Tourette syndrome in 13–14–year–olds in mainstream schools. J Child Psycol Psychiatry 42:1035–1039

    CAS  Google Scholar 

  49. Horrigan JP, Barnhill LJ (1995) Guanfacine for treatment of attentiondeficit hyperactivity disorder in boys. J Child Adolesc Psychopharmacol 5:215–223

    Article  Google Scholar 

  50. Hunt RD, Arnsten AFT, Asbell MD (1995) An open trial of guanfacine in the treatment of attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34:50–54

    CAS  PubMed  Google Scholar 

  51. Hyde TM, Aaronson BA, Randolph C, Rickler KC, Weinberger DR (1992) Relationship of birth weight to the phenotypic expression of Gilles de la Tourette’s syndrome in monozygotic twins. Neurology 42:652–658

    CAS  PubMed  Google Scholar 

  52. Jankovic J (1997) Tourette syndrome: phenomenology and classification of tics. Neurol Clin 15:267–275

    CAS  PubMed  Google Scholar 

  53. Jankovic J (2001) Tourette’s syndrome. N Engl J Med 345:1184–1192

    Article  CAS  PubMed  Google Scholar 

  54. Jankovic J (2001) Differential diagnosis and etiology of tics. Adv Neurol 85:15–29

    CAS  PubMed  Google Scholar 

  55. Jimenez–Jimenez FJ, Garcia–Ruiz PJ (2001) Pharmacological options for treatment of Tourette’s disorder. Drugs 61:2207–2220

    CAS  PubMed  Google Scholar 

  56. Kates WR, Frederikse M, Mostofsky SH, Folley BS, Cooper K, Mazur–Hopkins P, Kofman O, Singer HS, Denckla MB, Pearlson GD, Kaufmann WE (2002) MRI parcellation of the frontal lobe in boys with attention deficit hyperactivity disorder or Tourette syndrome. Psychiatry Res 116:63–81

    PubMed  Google Scholar 

  57. Kiessling LS, Marcotte AC, Culpepper L (1993) Antineuronal antibodies in movement disorders. Pediatrics 92:39–43

    CAS  PubMed  Google Scholar 

  58. King RA, Scahill L (2001) Emotional and behavioral difficulties associated with Tourette syndrome. Adv Neurol 85:79–88

    CAS  PubMed  Google Scholar 

  59. Kofoed L, Tadepalli G, Oesterheld JR, Awadallah S, Shapiro R (1999) Case series: clonidine has no systematic effects on PR or QTc intervals in children. J Am Acad Child Adolesc Psychiatry 38:1193–1196

    CAS  PubMed  Google Scholar 

  60. Kossoff EH, Singer HS (2001) Tourette syndrome: clinical characteristics and current management strategies. Paediatr Drugs 3:355–363

    CAS  PubMed  Google Scholar 

  61. Kumar R, Lang AE (1997) Tourette syndrome. Secondary tic disorders. Neurol Clin 15:309–331

    Article  CAS  PubMed  Google Scholar 

  62. Kurlan K, Lichter D, Hewitt D (1989) Sensory tics in Tourette’s Syndrome. Neurology 39:731–734

    CAS  PubMed  Google Scholar 

  63. Kurlan R, Como PG, Miller B (2002) The behavioural spectrum of tic disorders: a community–based study. Neurology 59:414–420

    CAS  PubMed  Google Scholar 

  64. Kurlan R (1997) Tourette syndrome. Treatment of tics. Neurol Clin 15:403–409

    CAS  PubMed  Google Scholar 

  65. Kurlan R (1998) Tourette’s syndrome and ‘PANDAS’:Will the relation bear out? Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection. Neurology 50:1530–1534

    CAS  PubMed  Google Scholar 

  66. Kwak C, Dat VK, Jankovic J (2003) Premonitory sensory phenomenon in Tourette’s syndrome. Mov Disord 18:1530–1533

    Article  PubMed  Google Scholar 

  67. Kwak C, Vuong KD, Jankovic J (2003) Migraine headache in patients with Tourette syndrome. Arch Neurol 60:1595–1598

    Article  PubMed  Google Scholar 

  68. Kwak CH, Hanna PA, Jankovic J (2000) Botulinum toxin in the treatment of tics. Arch Neurol 57:1190–1193

    Article  CAS  PubMed  Google Scholar 

  69. Lang AE (1991) Patient perception of tics and other movement disorders. Neurology 41:223–228

    CAS  PubMed  Google Scholar 

  70. Lang AE (2001) Update on the treatment of tics. Adv Neurol 85:355–362

    CAS  PubMed  Google Scholar 

  71. Lebovitz HE (2003) Metabolic consequences of atypical antipsychotic drugs. Psychiatr Q Fall 74:277–290

    Google Scholar 

  72. Leckman JF, Cohen DJ (1988) Descriptive and diagnostic classification of tic disorders. In: Cohen DJ, Bruun RD, Leckman JF (eds) Tourette's Syndrome and Tic Disorders: Clinical Understanding and Treatment. New York, NY: John Wiley and Sons, pp 3–21

  73. Leckman JF, Cohen DJ (1999) Tourette’s syndrome–Tics, Obsessions, Compulsions: Developmental Psychopathology and Clinical Care. New York: John Wiley and Sons

    Google Scholar 

  74. Leckman JF, Dolnansky ES, Hardin MT, Clubb M, Walkup JT, Stevenson J, et al. (1990) Perinatal factors in the expression of Tourette’s syndrome: an exploratory study. J Am Acad Child Adolesc Psychiatry 29:220–226

    CAS  PubMed  Google Scholar 

  75. Leckman JF, Hardin MT, Riddle MA, Stevenson J, Ort SI, Cohen DJ (1991) Clonidine treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 48:324–328

    CAS  PubMed  Google Scholar 

  76. Leckman JF, Katsovich L, Kawikova I, Lin H, Zhang H, Kronig H, Morshed S, Parveen S, Grantz H, Lombroso PJ, King RA (2005) Increased serum levels of interleukin–12 and tumor necrosis factor–alpha in Tourette’s syndrome. Biol Psychiatry 57:667–673

    Article  CAS  PubMed  Google Scholar 

  77. Leckman JF, Peterson BDS, Anderson GM, Arnsten ATF, Pauls DL, Cohen DJ (1997) Pathogenesis of Tourette’s syndrome. J Child Psychol Psychiatry 38:119–142

    CAS  PubMed  Google Scholar 

  78. Leckman JF, Peterson BS, King RA (2001) Phenomenology of tics and natural history of tic disorders. Adv Neurol 85:1–14

    CAS  PubMed  Google Scholar 

  79. Leckman JF, Peterson BS, Pauls DL, Cohen DJ (1997) Tic disorders. Psychiatr Clin North Am 20:839–861

    Article  CAS  PubMed  Google Scholar 

  80. Leckman JF, Riddle MA (2000) Tourette's syndrome: when habitforming systems form habits of their own? Neuron 28:349–354

    Article  CAS  PubMed  Google Scholar 

  81. Leckman JF, Walker DE, Cohen DJ (1993) Premonitory urges in Tourette's syndrome. Am J Psychiatry 150:98–102

    CAS  PubMed  Google Scholar 

  82. Lesperance P, Djerroud N, Diaz Anzaldua A, Rouleau GA, Chouinard S, Richer F;Montreal Tourette Study Group (2004) Restless legs in Tourette syndrome. Mov Disord 19:1084–1087

    CAS  PubMed  Google Scholar 

  83. Marcus D, Kurlan R (2001) Tics and its disorders. Neurol Clin 19:735–758

    Article  CAS  PubMed  Google Scholar 

  84. Marras C, Andrews D, Sime E, Lang AE (2001) Botulinum toxin for simple motor tics: a randomized, doubleblind, controlled clinical trial. Neurology 56:605–610

    CAS  PubMed  Google Scholar 

  85. Merette C, Brassard A, Potvin A, Bouvier H, Rousseau F, Emond C, et al. (2000) Significant linkage for Tourette syndrome in a large French Canadian family. Am J Hum Genet 67:1008–1013

    CAS  PubMed  Google Scholar 

  86. Mink JW (2003) The basal ganglia and involuntary movements. Arch Neurol 60:1365–1368

    Article  PubMed  Google Scholar 

  87. Mink JW (1996) The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol 50:381–425

    Article  CAS  PubMed  Google Scholar 

  88. Mink JW (2001) Neurobiology of basal ganglia circuits in Tourette syndrome: faulty inhibition of unwanted motor patterns? Adv Neurol 85:113–122

    CAS  PubMed  Google Scholar 

  89. Morshed SA, Parveen S, Leckman JF (2001) Antibodies against neural, nuclear, cytoskeletal, and streptococcal epitopes in children and adults with Tourette’s syndrome, Sydenham’s chorea, and autoimmune disorders. Biol Psychiatry 50:566–577

    Article  CAS  PubMed  Google Scholar 

  90. Mukaddes NM, Abali O (2003) Quetiapine treatment of children and adolescents with Tourette’s disorder. J Child Adolesc Psychopharmacol 13:295–299

    Article  PubMed  Google Scholar 

  91. Mullen N, Riedel M, Straube A, Gunther W, Wilske B (2000) Increased anti–streptococcal antibodies in patients with Tourette's syndrome. Psychiatry Res 94:43–49

    Google Scholar 

  92. Muller N (2004) Anti–inflammatory therapy with a COX–2 inhibitor in Tourette's syndrome. Inflammopharmacology 12:271–275

    PubMed  Google Scholar 

  93. Muller N, Riedel M, Blendinger C, Oberle K, Jacobs E, Abele–Horn M (2004) Mycoplasma pneumoniae infection and Tourette's syndrome. Psychiatry Res 129:119–125

    Article  PubMed  CAS  Google Scholar 

  94. Muller–Vahl KR (2002) The treatment of Tourette’s syndrome: current opinions. Expert Opin Pharmacother 3:899–914

    CAS  PubMed  Google Scholar 

  95. Muller–Vahl KR (2003) Cannabinoids reduce symptoms of Tourette's syndrome. Expert Opin Pharmacother 4:1717–1725

    PubMed  Google Scholar 

  96. Muller–Vahl KR, Kolbe H, Schneider U (1999) Cannabis in movement disorders. Forsch Komplementarmed 6:23–27

    PubMed  Google Scholar 

  97. Muller–Vahl KR, Meyer GJ, Knapp WH, Emrich HM, Gielow P, Brucke T, Berding G (2005) Serotonin transporter binding in Tourette Syndrome. Neurosci Lett (Epub ahead of print)

  98. Muller–Vahl KR, Prevedel H, Theloe K, Kolbe H, Emrich HM, Schneider U (2003) Treatment of Tourette syndrome with delta–9–tetrahydrocannabinol (delta 9–THC): no influence on neuropsychological performance. Neuropsychopharmacology 28:384–388

    PubMed  Google Scholar 

  99. Murphy TK, Bengtson MA, Soto O, Edge PJ, Sajid MW, Shapira N, Yang M (2005) Case series on the use of aripiprazole for Tourette syndrome. Int J Neuropsychopharmacol 28:1–2

    Google Scholar 

  100. Murphy TK, Goodman WK, Fudge MW (1997) B lymphocyte antigen D8/17: a peripheral marker for childhood– onset obsessive–compulsive disorder and Tourette's syndrome? Am J Psychiatry 154:402–407

    CAS  PubMed  Google Scholar 

  101. Niederhofer H, Staffen W, Mair A (2003) A placebo–controlled study of lofexidine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. J Psychopharmacol 17:113–119

    Article  CAS  PubMed  Google Scholar 

  102. Nordstrom EJ, Burton FH (2002) A transgenic model of comorbid Tourette's syndrome and obsessivecompulsive disorder circuitry. Mol Psychiatry 7:524

    Google Scholar 

  103. Olson S (2004) Neurobiology. Making sense of Tourette's. Science 305:1390–1392

    PubMed  Google Scholar 

  104. Onofrj M, Paci G, D'Andrea M, Toma L (2000) Olanzapine in severe Gilles de la Tourette syndrome: a 52–week double–blind cross–over study vs. low–dose pimozide. J Neurol 247:443–446

    Article  CAS  PubMed  Google Scholar 

  105. Orth M, Amann B, Robertson MM, Rothwell JC (2005) Excitability of motor cortex inhibitory circuits in Tourette syndrome before and after single dose nicotine. Brain 128:292–1300

    Article  Google Scholar 

  106. Parraga HC, Parraga MI, Woodward RL, Fenning PA (2003) Quetiapine treatment of children with Tourette's syndrome: report of two cases. J Am Acad Child Adolesc Psychiatry 42:623–624

    Google Scholar 

  107. Paschou P, Feng Y, Pakstis AJ, Speed WC, DeMille MM, Kidd JR, Jaghori B, Kurlan R, Pauls DL, Sandor P, Barr CL, Kidd KK (2004) Indications of linkage and association of Gilles de la Tourette syndrome in two independent family samples: 17q25 is a putative susceptibility region. Am J Hum Genet 75:545–560

    Article  CAS  PubMed  Google Scholar 

  108. Pauls DL (2001) Update on the genetics of Tourette syndrome. Adv Neurol 85:281–293

    CAS  PubMed  Google Scholar 

  109. Pauls DL (2003) An update on the genetics of Gilles de la Tourette syndrome. J Psychosom Res 55:7–12

    Article  PubMed  Google Scholar 

  110. Perlmutter SJ, Garvey MA, Castellanos X, Mittleman BB, Giedd J, Rapoport JL, Swedo SE (1998) A case of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. Am J Psychiatry 155:1592–1598

    CAS  PubMed  Google Scholar 

  111. Perry P, Gaffney G Pediatric Psychopharmacology: Tourette's Syndrome. Clinical Psychopharmacology Seminar 1996 Peer Review. Available from: http://www. vh. org/Providers/ Conferences/CPS/42. html 4

  112. Peterson AL, Azrin NH (1992) An evaluation of behavioral treatments for Tourette syndrome. Behav Res Ther 30:167–174

    CAS  PubMed  Google Scholar 

  113. Peterson BS, Thomas P, Kane MJ, Scahill L, Zhang H, Bronen R, King RA, Leckman JF, Staib L (2003) Basal Ganglia volumes in patients with Gilles de la Tourette syndrome. Arch Gen Psychiatry 60:415–424

    PubMed  Google Scholar 

  114. Plessen KJ, Wentzel–Larsen T, Hugdahl K, Feineigle P, Klein J, Staib LH, Leckman JF, Bansal R, Peterson BS (2004) Altered interhemispheric connectivity in individuals with Tourette's disorder. Am J Psychiatry 161:2028–2037

    Article  PubMed  Google Scholar 

  115. Pogarell O, Juckel G, Mulert C, Amann B, Möller HJ, Heger U (2004) EEG Abnormalities Under Treatment with Atypical Antipsychotics: Effects of Olanzapine and Amisulpride as Compared to Haloperidol. Pharmacopsychiatry 37:304–305

    Article  CAS  PubMed  Google Scholar 

  116. Porta M, Maggioni G, Ottaviani F, Schindler A (2004) Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A Neurol Sci 24:420–423

    Article  CAS  PubMed  Google Scholar 

  117. Posey DJ, Puntney JI, Sasher TM, Kem DL, McDougle CJ (2004) Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 14:233–241

    Article  PubMed  Google Scholar 

  118. Poyurovsky M, Bergman Y, Shoshani D, Schneidman M, Weizman A (1998) Emergence of obsessive–compulsive symptoms and tics during clozapine withdrawal. Clin Neuropharmacol 21:97–100

    CAS  PubMed  Google Scholar 

  119. Raffaele R, Vecchio I, Alvano A, Proto G, Nicoletti G, Rampello L (2004) Blink reflex abnormalities in Tourette sindrome. Clin Neurophysiol 115:320–324

    Article  PubMed  Google Scholar 

  120. Rampello L, Nicoletti G, Vecchio I (1995) Clinical and evolutive aspects of Tourette's syndrome. J Neurol 242:88

    Google Scholar 

  121. Rampello L, Vecchio I, Furnari P (2000) Tourette's sindrome: phenotipic and aetiopathogenetic spectrum. Mov Disord 15:248

    Google Scholar 

  122. Robertson MM (2000) Tourette syndrome, associated conditions and the complexities of treatment. Brain 123:425–462

    PubMed  Google Scholar 

  123. Rothenberger A, Kostanecka T, Kinkelbur J, Cohrs S, Woerner W, Hajak G (2001) Sleep and Tourette syndrome. In: Cohen DJ, Jankovic J, Goetz CG (eds) Tourette syndrome. Vol 85 of Advances in neurology. Philadelphia: Lippincott Williams and Wilkins, pp 245–259

  124. Ruth U, Mayer–Rosa J, Schlamp D, Freisleder FJ (2000) Tourette's syndrome and antidepressant therapy: exacerbation of nervous tics with paroxetine. Z Kinder Jugendpsychiatr Psychother 28:105–108

    CAS  PubMed  Google Scholar 

  125. Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G, Dittman VM, Chappell PB (2000) Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 39:292–299

    CAS  PubMed  Google Scholar 

  126. Sallee FR, Nesbitt L, Jackson C, Sine L, Sethuraman G (1997) Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry 154:1057–1062

    CAS  PubMed  Google Scholar 

  127. Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, Arnsten AF, Cohen DJ, Leckman JF (2001) A Placebo–Controlled Study of Guanfacine in the Treatment of Children With Tic Disorders and Attention Deficit Hyperactivity Disorder. Am J Psychiatry 158:1067–1074

    Article  CAS  PubMed  Google Scholar 

  128. Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS (2003) A placebo–controlled trial of risperidone in Tourette syndrome. Neurology 60:1130–1135

    CAS  PubMed  Google Scholar 

  129. T L, Tanner C, Dure L (2001) The epidemiology of tics and Tourette syndrome in children and adolescents. Adv Neurol 85:261–271

    PubMed  Google Scholar 

  130. Serrien DJ, Orth M, Evans AH, Lees AJ, Brown P (2005) Motor inhibition in patients with Gilles de la Tourette syndrome: functional activation patterns as revealed by EEG coherence. Brain 128:116–125

    PubMed  Google Scholar 

  131. Shapiro E, Shapiro AK, Fulop G, Hubbard M, Mandeli J, Nordlie J, Phillips RA (1989) Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 46:722–730

    CAS  PubMed  Google Scholar 

  132. Silay YS, Jankovic J (2005) Emerging drugs in Tourette syndrome. Expert Opin Emerg Drugs 10:365–380

    Article  CAS  PubMed  Google Scholar 

  133. Silver AA, Shytle RD, Philipp MK (2001) Transdermal nicotine and haloperidol in Tourette's disorder: a double–blind placebo–contolled study. J Clin Psychiatry 62:707–714

    Article  CAS  PubMed  Google Scholar 

  134. Simonic I, Nyholt DR, Gericke, GS, Gordon D, Matsumoto N, Ledbetter DH, Ott J, Weber JL (2001) Further evidence for linkage of Gilles de la Tourette syndrome (GTS) susceptibility loci on chromosomes 2p11, 8q22, and 11q23–24 in South African Afrikaners. Am J Med Genet 105:163–167

    Article  CAS  PubMed  Google Scholar 

  135. Singer HS (1995) Neurobiology of Tourette syndrome Biol Psychiatry 37:629

    Google Scholar 

  136. Singer HS (2000) Current issues in Tourette Syndrome. Mov Disord 15:1051–1063

    Article  CAS  PubMed  Google Scholar 

  137. Singer HS (2005) Tourette's syndrome: from behaviour to biology. Lancet Neurol 4:149–159

    PubMed  Google Scholar 

  138. Singer HS, Giuliano JD, Hansen BH, Hallett JJ, Laurino JP, Benson M, Kiessling LS (1998) Antibodies against human putamen in children with Tourette syndrome. Neurology 50:1618–1624

    CAS  PubMed  Google Scholar 

  139. Singer HS, Giuliano JD, Hansen BH, et al. (1999) Antibodies against a neuron–like (HTB10 neuroblastoma) cell in children with Tourette syndrome. Biol Psychiatry 46:775–780

    Article  CAS  PubMed  Google Scholar 

  140. Singer HS, Krumholz A, Giuliano J, Kiessling LS (1997) Antiphospholipid antibodies: an epiphenomenon in Tourette syndrome. Mov Disord 12:738–742

    CAS  PubMed  Google Scholar 

  141. Smith JL, Johnstone SJ, Barry RJ (2004) Inhibitory processing during the Go/NoGo task: an ERP analysis of children with attention–deficit/hyperactivity disorder. Clin Neurophysiol 115:1320–1331

    Article  PubMed  Google Scholar 

  142. Smith SJ, Lees AJ (1989) Abnormalities of the blink reflex in Gilles de la Tourette syndrome. J Neurol Neurosurgery Psychiatry 52:895–898

    Article  CAS  Google Scholar 

  143. State MW, Greally JM, Cuker A, Bowers PN, Henegariu O, Morgan TM, et al. (2003) Epigenetic abnormalities associated with a chromosome 18(q21–q22) inversion and a Gilles de la Tourette syndrome phenotype. Proc Natl Acad Sci USA 100:4684–4689

    Article  CAS  PubMed  Google Scholar 

  144. Stein DJ (2002) Obessive–compulsive disorder. Lancet 360:397–405

    Article  PubMed  Google Scholar 

  145. Stephens RJ, Bassel C, Sandor P (2004) Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome–a pilot study. J Child Adolesc Psychopharmacol 14:255–266

    Article  PubMed  Google Scholar 

  146. Stern JS, Burza S, Robertson MM (2005) Gilles de la Tourette's syndrome and its impact in the UK. Postgrad Med J 81:12–19

    Article  CAS  PubMed  Google Scholar 

  147. Tatlipinar S, Iener EC, Ilhan B (2001) Ophtalmic manifestations of Gilles de la Tourette syndrome. Eur Ophtalmol 11:223–226

    CAS  Google Scholar 

  148. Temel Y, Visser–Vandewalle V (2004) Surgery in Tourette syndrome. Mov Disord 19:3–14

    Article  PubMed  Google Scholar 

  149. The Tourette Syndrome Association International Consortium for Genetics (1999) A complete genome screen in sib pairs affected by Gilles de la Tourette syndrome. Am J Hum Genet 65:1428–1436

    Google Scholar 

  150. The Tourette Syndrome Classification Study Group (1993) Definitions and classification of tic disorders. Arch Neurol 50:1013–1016

    Google Scholar 

  151. Tolchard B (1995) Treatment of Gilles de la Tourette syndrome using behavioural psychotherapy: a single case example. J Psychiatr Ment Health Nurs 2:233–236

    CAS  PubMed  Google Scholar 

  152. Toren P, Toren A, Weizman A, Mozes T, Eldar S, Magor A, Mandel M, Rechavi G, Many A, Mester R (1994) Tourette's disorder: is there an association with the antiphospholipid syndrome? Biol Psychiatry 35:495–498

    CAS  PubMed  Google Scholar 

  153. Toren P, Weizman A, Ratner S, Cohen D, Laor N (2005) Ondansetron treatment in Tourette's disorder: a 3–week, randomized, double–blind, placebocontrolled study. J Clin Psychiatry 66:499–503

    Article  CAS  PubMed  Google Scholar 

  154. Tourette's Syndrome Study Group (2002) Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58:527–536

    Google Scholar 

  155. Vandewalle V, van der Linden C, Groenewegen HJ (1999) Stereotactic treatment of Gilles de la Tourette syndrome by high frequency stimulation of thalamus. Lancet 353:724

    Article  CAS  PubMed  Google Scholar 

  156. Verdellen CW, Keijsers GP, Cath DC, Hoogduin CA (2004) Exposure with response prevention versus habit reversal in Tourettes's syndrome: a controlled study. Behav Res Ther 42:501–511

    PubMed  Google Scholar 

  157. Verkerk AJ, Mathews CA, Joosse M, Eussen BH, Heutink P, Oostra BA, and the Tourette Syndrome Association International Consortium for Genetics (2003) CNTNAP2 is disrupted in a family with Gilles de la Tourette syndrome and obsessive compulsive disorder. Genomics 82:1–9

    Article  CAS  PubMed  Google Scholar 

  158. Voelker R (2004) Scientists use neuroimaging, genetic studies to probe biology of tourette syndrome. JAMA 292:909–911

    CAS  PubMed  Google Scholar 

  159. Walkup JT, LaBuda MC, Singer HS, Brown J, Riddle MA, Hurko O (1996) Family study and segregation analysis of Tourette syndrome: evidence for a mixed model of inheritance. Am J Hum Genet 59:684–693

    CAS  PubMed  Google Scholar 

  160. Wilhelm S, Deckersbach T, Coffey BJ, Bohne A, Peterson AL, Baer L (2003) Habit Reversal Versus Supportive Psychotherapy for Tourette's Disorder: A Randomized Controlled Trial. Am J Psychiatry 160:1175–1177

    Article  PubMed  Google Scholar 

  161. Wolf SS, Jones DW, Knable MB, Gorey JG, Lee KS, Hyde TM, et al. (1996) Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science 273:1225–1227

    CAS  PubMed  Google Scholar 

  162. Woods DW, Twohig MP, Flessner CA, Roloff TJ (2003) Treatment of vocal tics in children with Tourette syndrome: investigating the efficacy of habit reversal. J Appl Behav Anal 36:109–112

    PubMed  Google Scholar 

  163. Zhang H, Leckman JF, Pauls DL, Tsai CP, Kidd KK, Campos MR (2002) Genome wide scan of hoarding in sib pairs in which both sibs have Gilles de la Tourette syndrome. Am J Hum Genet 70:896–904

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to L. Rampello.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rampello, L., Alvano, A., Battaglia, G. et al. Tic disorders: from pathophysiology to treatment. J Neurol 253, 1–15 (2006). https://doi.org/10.1007/s00415-005-0008-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-005-0008-8

Key words

Navigation